Why the study?
The study was conducted to investigate the effect of astragaloside IV on podocyte pyroptosis in diabetic kidney disease.
Does astragaloside IV reduce podocyte pyroptosis in diabetic kidney disease models?
Population
40 male Sprague-Dawley rats and rat podocytes
Comparison
Astragaloside IV vs UBCS039 vs saline
Design
Randomized preclinical animal and in vitro study
Follow-up
8 weeks
Key result
Astragaloside IV alleviated podocyte pyroptosis and inhibited ROS in rats with diabetic kidney disease by regulating the SIRT6/HIF-1α pathway.
Authors
Loading...
AS may attenuate podocyte pyroptosis in rat DKD; leaves open translation to human therapy.
Does astragaloside IV reduce podocyte pyroptosis in diabetic kidney disease models?
Astragaloside IV may protect against diabetic kidney disease by inhibiting podocyte pyroptosis via the SIRT6/HIF-1α pathway.
Zhang et al. (2023) studied Diabetic kidney disease (n=40). Astragaloside IV (AS) vs. Saline was evaluated on Podocyte pyroptosis and ROS levels. Astragaloside IV alleviated podocyte pyroptosis and inhibited ROS in rats with diabetic kidney disease by regulating the SIRT6/HIF-1α pathway.